摘要 |
<p>Methods and agents are provided for treatment of disorders associated with aberrant adrenocortical cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC) and/or Cushing's syndrome. Such methods involve administration of an agent which exhibits an IC50 value against huACAT1 of less than 10 µM, and one or more further characteristics including effects on adrenocortical cells, disruption of cholesterol homeostasis, reduction in steroid biosynthesis, reduction of mitochondrial function, and/or preferential binding to by low-density lipoprotein (LDL).</p> |
申请人 |
ATTEROCOR, INC.;RAINEY, WILLIAM, E., JR.;LAPENSEE, CHRISTOPHER, R.;HAMMER, GARY, D. |
发明人 |
RAINEY, WILLIAM, E., JR.;LAPENSEE, CHRISTOPHER, R.;HAMMER, GARY, D.;HUNT, STEPHEN, WARREN, III;OWENS, JULIA, CHRISTINE |